Dennies Varughese, Pharm.D. "Confident and assertive, but never brash, he digs deep to deliver spirited advocacy that compels decision makers to rule in his favour." - IAM Patent 1000

Dennies Varughese, Pharm.D.

+1 202.772.8805


Dennies Varughese, Pharm.D., a director in Sterne Kessler’s Trial & Appellate Practice Group, is a trial attorney and globally recognized strategic advisor for pharmaceutical clients. Dennies specializes in the full range of intellectual property disputes, having handled numerous high-stakes patent and trademark litigation in district courts, as well as many contested proceedings before the U.S. Patent Trial and Appeal Board (“PTAB”) at the Patent Office.

Ranked as a leading life sciences litigator by various national accrediting agencies, Dennies has been lead trial counsel on dozens of high-stakes district court cases and PTAB matters involving blockbuster pharmaceuticals, on both the brand and generic side, including: Abilify® (aripiprazole), Zytiga® (abiraterone), Dymista® (azelastine/fluticasone), Cialis® (tadalafil), Gilenya® (fingolimod), Nexium 24® (esomeprazole OTC), Revlimid® (lenalidomide), and many others. Notably, he successfully defeated injunction motions clearing the way for first-wave generics into the lucrative market for Abilify®, at that time the largest pharmaceutical litigation ever. Dennies has also handled many cases for market leaders in other industries, including biopharmaceuticals, chemicals, medical devices, diagnostics, telecommunications, and electronics.

In addition to patent disputes, Dennies has extensive experience in anti-counterfeiting and trademark enforcement. He served as lead counsel for Juul Labs, Inc. in various trademark and trade dress disputes against unauthorized copyists of Juul’s highly successful Electronic Nicotine Delivery Systems.

Dennies also has an active practice before the PTAB involving inter partes review (“IPR”) and post-grant review (“PGR”) proceedings. He was involved in the first ever IPR filed in an ANDA case (Vigamox®) in 2012, and served as lead counsel in the only to-date CBM in a pharmaceutical case (Xyrem®). A full listing of Dennies’ representative matters before the PTAB can be found below. Dennies is a contributing author of Patent Office Litigation, a comprehensive treatise exploring all aspects of contested proceedings before the Patent Office.

Dennies, a frequent lecturer and author, is often quoted in legal publications and is a thought leader on Paragraph IV disputes. He is sought after by generic and brand companies alike for strategic advice on FDA regulatory and early commercialization strategies, product targeting, 505(b)(2) product design, at-risk launch, 180-Day marketing exclusivity and forfeiture, labeling carve-outs, patent settlement and licensing, supply and distribution agreements, drug products liability, and antitrust issues bearing on patent settlements.

Prior to his legal career, Dennies completed a post-doctoral fellowship at Bristol-Myers Squibb Co., worked within GlaxoSmithKline’s Medical Affairs division, and served as an adjunct professor of pharmacy at Rutgers University. He was also a licensed pharmacist in Pennsylvania.

Dennies received his J.D. from Temple University Beasley School of Law. In law school, he was a member of the Temple Law Review, was awarded the Barrister Award for excellence in trial advocacy, the Podwil Memorial Prize for excellence in intellectual property, and the Matkoff Scholarship award. He graduated with honors, cum laude. He earned his Pharm.D. from the University of the Sciences, Philadelphia.

Dennies grew up in Philadelphia and he loves the Philadelphia Eagles.

Representative Matters

Hatch-Waxman Litigation Engagements

  • AstraZeneca Pharmaceuticals LP v. Intas Pharmaceutical Ltd. (currently representing Intas in Hatch Waxman litigation over SEROQUEL® XR) (D.N.J.) (08-cv-04804)
  • AstraZeneca Pharmaceuticals LP v. Glenmark Generics, Inc. (currently representing Glenmark in multiple Hatch Waxman patent litigations over CRESTOR®) (D. Del.) (10-cv-00341; 10-cv-00543
  • Takeda Pharmaceuticals Co. v. Torrent Pharmaceuticals Ltd. (represented Torrent in Hatch Waxman patent litigation over ACTOS®) (S.D.N.Y.) (09-cv-6051)
  • GlaxoSmithKline v. Glenmark Generics, Inc. (represented Glenmark in Hatch Waxman patent litigation over MALARONE®) (D. Del) (09-cv-00608)

Patent Litigation Engagements

  • Teva v. Glenmark Pharmaceuticals, Inc. (represented Glenmark in patent litigation over carvedilol) (D.N.J.) (08-cv-4355)
  • Typhoon Touch Technologies v. Motion Computing et al.(represented Typhoon Touch in patent litigation over portable touch screen computers) (E.D. Tex) (07-cv-00546)
  • Nexans, Inc. v. General Cable Corporation (represented General Cable in patent litigation over high-speed data communication cables) (E.D. Pa.) (07-cv-02296)
  • Nutrition 21, Inc. v. General Nutrition Company (assisted in representation of Nutrition 21 in patent litigation over chromium picolinate) (E.D. Tex) (05-cv-00291)

PTAB Engagements

  • Amneal Pharmaceuticals LLC et al. v. Allergan, Inc. et al. (representing Amneal in IPR proceedings concerning an acne drug) (IPR2018-00608, IPR2019-00207)
  • Argentum Pharmaceuticals LLC et al. v. Cipla Limited et al. (represented Cipla in an IPR of a patent covering DYMISTA®) (IPR2017-00807)
  • Wockhardt Bio AG et al. v. Janssen Oncology, Inc. et al. (represented Wockhardt in an IPR of a patent covering ZYTIGA®) (IPR2016-01582)
  • Wockhardt Bio AG v. Jazz Pharmaceuticals, Inc. (represented Wockhardt in an IPR of a patent claiming microbe-resistant formulations) (IPR2016-00370)
  • Amneal Pharmaceuticals LLC v. Jazz Pharmaceuticals, Inc. (IPR2015-00547, -00546, -00545) (CMB2014-00150, -00149)
  • Amneal Pharmaceuticals LLC v. Endo Pharmaceuticals, Inc. (IPR2014-01365, -00361, -00360, 00160)
  • Ricoh Americas Corporation v. MPHJ Technology Investments, Inc. (IPR 2013-00302)


  • IAM Patent 1000, “Washington, D.C.: Patent Litigation (Bronze Band)” (2024 – 2018)
  • LMG Life Sciences, “Life Sciences Star” (2023 – 2018)
  • Super Lawyers, “Super Lawyer – Washington D.C.” (2024 – 2018)
  • Super Lawyers, “Rising Star – Washington D.C.” (2017 – 2014)


  • J.D., Temple University Beasley School of Law, cum laude
  • Pharm.D., University of the Sciences


  • District of Columbia
  • New Jersey
  • Pennsylvania
  • United States Patent & Trademark Office


Speaking Engagement 2023 Focus on Pharma Washington, DC, April 14, 2023
Speaking Engagement International IP Skills Summit (IIPSS) Hyderabad, India, February 26, 2020
Speaking Engagement 13th Annual Paragraph IV Disputes New York, NY, April 29, 2019
4th Annual Pharma IPR India February 11, 2015

Related News & Insights From Dennies Varughese, Pharm.D.

Press Release Eighteen Sterne Kessler Attorneys Recognized as 2024 “Super Lawyers” and “Rising Stars” Sterne, Kessler, Goldstein & Fox April 25, 2024
Firm Announcements Federal Circuit Affirms Sweet Win for SweeGen in Patent Invalidity Battle Sterne, Kessler, Goldstein & Fox January 3, 2024
In the News Fed. Circ. Judge Casts Doubt On Sweetener Enzyme Patents Law360 November 7, 2023
Press Release LMG Life Sciences Ranks Sterne Kessler and Seven Directors for Patent Litigation and Prosecution Sterne, Kessler, Goldstein & Fox September 21, 2023
Firm Announcements U.S. District Court Affirms Immigrant Children’s Constitutional Rights Sterne, Kessler, Goldstein & Fox August 29, 2023
In the News Novartis Tells FDA Skinny Labels Won't Work With $3.5B Drug Law360 September 15, 2022
In the News Gilead Settles HIV Drugs Patent Suit on Eve of Bench Trial Law360 September 12, 2022
Firm Announcements Sterne Kessler Client Catalyst Pharmaceuticals, Inc. Reaches Patent Litigation Settlement Sterne, Kessler, Goldstein & Fox July 14, 2022
In the News Stevia Patent Claims Fall After SweeGen Challenge Law360 May 24, 2022
Press Release Super Lawyers Recognizes 14 Attorneys as 2022 “Super Lawyers” and “Rising Stars” Sterne, Kessler, Goldstein & Fox May 1, 2022
In the News Almirall Loses Appeal on Acne Treatment Patent at Fed. Cir. Bloomberg Law March 14, 2022
In the News Fed. Circ. Affirms PTAB's Ax of Acne Drug Patent Law360 March 14, 2022
Press Release Sterne Kessler and Seven Directors Earn Top-Tier Designations in 2021 LMG Life Sciences Rankings Sterne, Kessler, Goldstein & Fox September 29, 2021
In the News How Counsel Balance USPTO and Court Edicts on Section 101 Managing IP March 4, 2021
Press Release Firm and Seven Directors Recognized in 2020 LMG Life Sciences Rankings Sterne, Kessler, Goldstein & Fox P.L.L.C. October 6, 2020
Press Release Sterne, Kessler, Goldstein & Fox Wins Two 2020 LMG Life Sciences Americas Awards Sterne, Kessler, Goldstein & Fox P.L.L.C. September 24, 2020
Press Release Sterne, Kessler, Goldstein & Fox and 15 Directors Earn Top Rankings in IAM Patent 1000 Sterne, Kessler, Goldstein & Fox P.L.L.C. June 16, 2020
Press Release Sterne, Kessler, Goldstein & Fox Attorneys Named 2020 Super Lawyers and Rising Stars Sterne, Kessler, Goldstein & Fox P.L.L.C. April 30, 2020
Press Release Sterne Kessler Prominent Again in Intellectual Asset Management Magazine’s "IAM Patent 1000" Sterne, Kessler, Goldstein & Fox P.L.L.C June 12, 2019
In the News J&J Tells Fed. Circ. Judge Was Wrong To Nix Zytiga Patent Law360 December 4, 2018
Press Release Sterne Kessler Recognized By LMG Life Sciences Among The Top IP Firms and Attorneys Sterne, Kessler, Goldstein & Fox September 25, 2018
Firm Announcements Sterne Kessler Prevails in the Release of Child from a Juvenile Detention Center Sterne, Kessler, Goldstein & Fox July 26, 2018
Firm Announcements Sterne Kessler Successfully Represents Alembic Pharmaceuticals Limited in Launching Generic Drug fivejars April 16, 2015 Chandrika Vira, Dennies Varughese, Pharm.D.
In the News Glenmark Sues Sanofi to Clear Way for Antidiuretic Law360 April 16, 2014